Moderna Boss Defends UK Amid Pharma Pricing Row as New Oxfordshire Facility Opens
The UK head of US pharmaceutical giant Moderna has defended the country against criticism from some of the world’s biggest drugmakers, saying the company remains committed to investing in Britain despite ongoing disputes over drug pricing.
Darius Hughes, Moderna’s UK general manager, made the comments as he officially opened a £150 million vaccine manufacturing site in Oxfordshire, highlighting the company’s long-term commitment to the UK market.
Pharma Industry Criticism
The remarks come amid growing tensions between the UK government and several major pharmaceutical companies. Executives from MSD, AstraZeneca, and Eli Lilly have recently signalled plans to pause or cancel investments in the UK, citing frustration with the government’s pricing policies.
Eli Lilly’s chief executive, Dave Ricks, described the UK as “probably the worst country in Europe” for drug prices, arguing that the nation’s strict cost controls risk making it a less attractive market for new treatments. Similar comments have been made by other pharma leaders, warning that restrictive pricing could limit patient access to innovative drugs.
Moderna’s Commitment
Hughes struck a different tone. He said that while some companies may see challenges in the UK market, Moderna remains fully committed to its 10-year, £1 billion partnership with the government, which includes significant research and development (R&D) investment.
“We’re here to invest,” Hughes said. “We’re here on a 10-year strategic partnership, and we will be investing heavily in R&D across that period.”
The Oxfordshire facility, which Moderna says will produce vaccines for both COVID-19 and other diseases, marks the company’s largest investment in the UK to date. Hughes emphasized that the site is a signal of confidence in the UK’s scientific infrastructure and regulatory environment.
Government and Industry Dynamics
The debate over drug pricing in the UK has intensified as the government seeks to balance affordability for the National Health Service (NHS) with incentives for pharmaceutical companies to bring new medicines to the market.
Hughes described some of the criticism from other companies as “a little harsh,” suggesting that the UK remains a competitive environment for investment despite its strict pricing rules.
“We are seeing opportunities to expand our footprint and capabilities here,” he added. “We believe that our partnership with the UK government allows us to innovate while providing medicines that benefit patients.”
The Role of Pricing Policies
The controversy centers on the UK’s ability to negotiate lower drug prices compared to other developed countries. While this strategy benefits the NHS and patients in the short term, some pharma executives argue it could discourage long-term investment and delay the introduction of new treatments.
Hughes’ remarks indicate that Moderna sees value in working within the UK system, focusing on collaboration and innovation rather than publicly critiquing government policies.
Oxfordshire Facility: A Strategic Move
The new £150 million site in Oxfordshire is part of Moderna’s global expansion strategy. The facility will not only manufacture COVID-19 vaccines but also support the company’s pipeline of mRNA-based medicines targeting other infectious diseases and potentially even cancer treatments.
Hughes emphasized that the UK’s skilled workforce, research capabilities, and supportive infrastructure were key factors in choosing Oxfordshire for the investment.
“We believe the UK provides an environment where we can scale up production and advance our scientific mission,” Hughes said.
Pharma Industry Outlook
The UK continues to be a key market for global pharmaceutical companies, despite criticisms over pricing. Moderna’s decision to invest heavily contrasts with other firms considering scaling back, signaling that the UK can still attract major R&D projects when companies see long-term strategic benefits.
Industry observers suggest that the Moderna announcement may encourage other companies to reconsider their positions, showing that partnerships and infrastructure can outweigh pricing concerns in some cases.
Moderna’s UK boss has positioned the company as a long-term partner to the government, contrasting sharply with other pharmaceutical executives who have criticized the country’s drug pricing policies. The opening of the Oxfordshire vaccine facility demonstrates a strong commitment to investment, innovation, and collaboration in the UK market, even amid wider industry debate.
As the UK government continues to balance affordability and innovation, Moderna’s move may signal that a collaborative approach between pharma companies and policymakers can still deliver major investments and advances in healthcare.
